DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category Homepage Promo Block

Looking for More Biotech Reports?

I publish daily updates, FDA catalyst calendars, run-up analyses and
full breakdowns of micro and mid-cap biotech names.
You can find all the latest reports on the homepage.


Visit the Merlintrader Homepage →

LXRX Lexicon Pharmaceuticals Inc

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products using its proprietary gene science approach. The company operates in two segments: Product (INPEFA® commercialization) and Licensing (Novo Nordisk partnership for LX9851 obesity program).

ONMD OneMedNet Corporation

onmd

OneMedNet Corporation (NASDAQ: ONMD) is a healthcare technology company specializing in curating and providing regulatory-grade Real-World Data (RWD) through its proprietary iRWD™ platform. The company connects life sciences organizations, medical device companies, and AI researchers with de-identified medical imaging, electronic health records, and clinical data from over 2,130 healthcare provider sites spanning 47+ million unique patient lives and 186+ million clinical exams.

MBOT Microbot Medical Inc.

MBOT Liberty

Microbot Medical is a commercial-stage medical device company specializing in endovascular robotic systems. The company achieved a transformational milestone in September 2025 with FDA 510(k) clearance for its flagship LIBERTY® Endovascular Robotic System - the world's first FDA-cleared single-use, remotely operated robotic platform for peripheral endovascular procedures.

VRCA Verrica Pharmaceuticals Inc

VRCAd060902821i 1

Verrica Pharmaceuticals [finance:Verrica Pharmaceuticals Inc.] (NASDAQ: VRCA) is a commercial-stage dermatology biopharmaceutical company focused on developing and commercializing innovative medical aesthetic solutions for skin conditions including molluscum contagiosum, basal cell carcinoma, and aesthetic dermatology indications. The company operates through a partnership model, leveraging strategic alliances with larger pharmaceutical companies (Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.]) for commercialization and geographic expansion.

ACRS Aclaris Therapeutics Inc

acrs

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage dermatology-focused biopharmaceutical company developing innovative immunological therapies for inflammatory and immune-mediated skin diseases. The company transitioned from a commercial-stage company with FDA-approved products to a clinical-stage organization, strategically acquiring promising pipeline assets to build a competitive portfolio in atopic dermatitis and related indications.

AMRN Amarin Corp

AMRN

? Amarin Corporation (AMRN) – Company History & Analysis ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice,…

NRXP

NRXP

NRx Pharmaceuticals (NRXP) | Investment Research Report ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT…

CUE Biopharma

CUE

Cue Biopharma (CUE) | Investment Research Report ?? English Version ? Cue Biopharma (CUE) Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators Update: November 26, 2025 ⚠️ GOING CONCERN WARNING ? STRATEGIC PIVOT TO AUTOIMMUNE NASDAQ: CUE | Price:…

CAPR Capricor

CAPR Santa

Capricor Therapeutics [finance:Capricor Therapeutics, Inc.] is a clinical‑stage biotech focused on cell and exosome‑based therapeutics for rare diseases, with lead asset Deramiocel (CAP‑1002) targeting cardiomyopathy in Duchenne muscular dystrophy

ADMA BIOLOGICS

ADMA

ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033).

OSCR Oscar Health

oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary…